Alphatec Holdings (ATEC) Resumen de Acciones
Alphatec Holdings, Inc. es una empresa de tecnología médica que diseña, desarrolla y avanza tecnologías para el tratamiento quirúrgico de trastornos de la columna vertebral en Estados Unidos y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 5/6 |
| Crecimiento futuro | 5/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 2/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
ATEC Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Alphatec Holdings, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$8.27 |
| Máximo en las últimas 52 semanas | US$23.29 |
| Mínimo de 52 semanas | US$6.82 |
| Beta | 0.97 |
| Cambio en 1 mes | -22.13% |
| Variación en 3 meses | -36.43% |
| Cambio de 1 año | -33.57% |
| Variación en 3 años | -42.25% |
| Variación en 5 años | -42.97% |
| Variación desde la OPV | -92.33% |
Noticias y actualizaciones recientes
Seeking Alpha • May 19
Alphatec - Slower Growth Seems Priced In Here
Summary Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability. Slowing topline growth and elusive margins temper enthusiasm, but current valuation appears compelling versus medtech peers, making Alphatec a speculative yet interesting play. Read the full article on Seeking Alpha
Actualización de narrativa • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).Recent updates
Seeking Alpha • May 19
Alphatec - Slower Growth Seems Priced In Here
Summary Alphatec Holdings shares have dropped two-thirds YTD, now trading at just over 2x sales, reflecting sharply decelerating growth and persistent losses. Q1 2026 revenue grew only 14% to $192.1M, prompting a slight full-year sales guidance cut; adjusted EBITDA margins improved but remain heavily adjusted. Despite a $466M net debt load and ongoing dilution, Alphatec demonstrates real operating leverage, with manageable losses and a credible path toward profitability. Slowing topline growth and elusive margins temper enthusiasm, but current valuation appears compelling versus medtech peers, making Alphatec a speculative yet interesting play. Read the full article on Seeking AlphaActualización de narrativa • May 14
ATEC: 2026 Surgical Revenue Focus Will Support Future Upside Potential
Analysts have reduced their price target for Alphatec Holdings from about $24.62 to about $17.33 as they adjust assumptions for discount rate, revenue growth, profit margin, and future P/E in their models. What's in the News Alphatec Holdings issued earnings guidance for the fiscal year ending December 31, 2026, targeting total revenue of about $882 million, with surgical revenue expected to grow 17% as part of that outlook (corporate guidance).
Actualización de narrativa • Apr 29
ATEC: 2026 Revenue Guidance Will Drive Constructive Upside Case
Analysts have kept their $28.00 price target for Alphatec Holdings unchanged, noting that only modest adjustments to assumptions around discount rate, revenue growth, profit margin and future P/E offset one another in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, indicating no change to its previously communicated outlook.Actualización de narrativa • Apr 15
ATEC: 2026 Revenue Outlook Will Support Bullish Return Potential
Analysts have kept their $28.00 price target on Alphatec Holdings unchanged, citing updated assumptions that include a higher discount rate, stronger modeled revenue and profit margins, and a lower future P/E multiple that together balance out in their valuation work. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, maintaining its outlook for that period.
Actualización de narrativa • Mar 31
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside
Analysts have trimmed their price target for Alphatec Holdings from $22.00 to $20.00, citing updated assumptions for revenue growth, profit margins and future P/E that together point to a more measured long term outlook for the shares. What's in the News Reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% above full year 2025 revenue (Corporate Guidance).Actualización de narrativa • Mar 17
ATEC: 2026 Revenue Outlook And Spine Biologics Partnership Will Support Upside
Analysts have left their $28.00 price target for Alphatec Holdings unchanged, citing a slightly higher assumed discount rate, a moderated revenue growth outlook, stronger projected profit margins, and a lower future P/E as key factors supporting the steady valuation. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million.Actualización de narrativa • Mar 03
ATEC: 2026 Revenue Outlook And Biologics Partnership Will Support Upside Potential
Analysts have adjusted their Alphatec Holdings target to $24.62, reflecting updated assumptions that combine slightly lower expected revenue growth with higher projected profit margins and a reduced future P/E multiple, while applying a somewhat higher discount rate. What's in the News Alphatec Holdings reaffirmed earnings guidance for the fiscal year ending December 31, 2026, with total revenue expected to approximate $890 million, described as about $126 million or 17% higher than full year 2025 revenue (company guidance).Actualización de narrativa • Feb 17
ATEC: 2026 Revenue Guidance And Spine Biologics Deal Will Drive Upside
Analysts have maintained their $28.00 price target for Alphatec Holdings, citing steady model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions as reasons to hold their prior valuation line. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately $890m for the year ended December 31, 2026 (Corporate Guidance).Actualización de narrativa • Feb 03
ATEC: Partnership And 2026 Revenue Outlook Will Reshape Spine Biologics Opportunity
Analysts have raised their fair value estimate for Alphatec Holdings from $23.00 to $28.00, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E that they believe better reflect the company’s current outlook. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of about $890 million compared to full year 2025 (Corporate Guidance).Actualización de narrativa • Jan 20
ATEC: Higher 2026 Revenue Outlook And New Partnership Will Support Upside
Analysts have lifted their price target on Alphatec Holdings from US$14.00 to US$22.00, citing updated assumptions around discount rate, revenue growth, profit margins and future P/E as the key drivers of the change. What's in the News Alphatec Holdings issued revenue guidance for fiscal 2026, indicating expected total revenue of approximately US$890 million for the year.Artículo de análisis • Jan 06
Are Alphatec Holdings, Inc. (NASDAQ:ATEC) Investors Paying Above The Intrinsic Value?
Key Insights Alphatec Holdings' estimated fair value is US$17.32 based on 2 Stage Free Cash Flow to Equity Alphatec...Actualización de narrativa • Jan 06
ATEC: Higher 2025 Revenue Guidance Will Support A More Optimistic Outlook
Analysts have inched their price target for Alphatec Holdings higher to about $24.62 from $24.00, reflecting small tweaks to fair value estimates, discount rate assumptions, and a slightly higher future P/E multiple in their models. What's in the News Alphatec Holdings raised earnings guidance for the fiscal year ending December 31, 2025, indicating updated expectations for the business outlook.Actualización de narrativa • Dec 14
ATEC: Revenue Will Reach 760 Million As Outlook Remains Favorable
Analysts have modestly raised their price target on Alphatec Holdings by 0.25 dollars to 24.00 dollars, reflecting slightly higher long term valuation multiples despite only marginal tweaks to growth, margin and discount rate assumptions. What's in the News Alphatec Holdings raised its earnings guidance for fiscal 2025, now expecting total revenue to increase 24 percent to 760 million dollars, compared with the prior outlook of 742 million dollars (company guidance filing) Valuation Changes Fair Value Estimate has risen slightly to 24.00 dollars from 23.75 dollars, reflecting a modest uplift in long term valuation.Actualización de narrativa • Nov 29
ATEC: Revenue Will Reach $760 Million As Guidance Increases And Outlook Remains Steady
Analysts have maintained their fair value price target for Alphatec Holdings at $23.75, citing only minor adjustments to underlying financial assumptions along with a steady outlook for growth and profitability. What's in the News Alphatec Holdings raised its earnings guidance for the fiscal year ending December 31, 2025, reflecting increased confidence in the company's outlook (Key Developments).Actualización de narrativa • Nov 15
ATEC: Total Revenue Will Reach $760 Million Next Year
Narrative Update on Alphatec Holdings: Analyst Price Target Revision Analysts have increased their price target for Alphatec Holdings from $20.54 to $23.75. This change reflects revised financial assumptions and updated expectations for the company’s future performance.Actualización de narrativa • Nov 01
ATEC: Improved Margins And Revenue Projections Will Shape Future Performance
Analysts have raised their price target for Alphatec Holdings from $19.41 to $20.54 per share, citing improved profit margin forecasts and stronger projected revenue growth as key reasons for the increased valuation. What's in the News Alphatec Holdings, Inc.Artículo de análisis • Oct 05
Not Many Are Piling Into Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Yet
With a median price-to-sales (or "P/S") ratio of close to 2.8x in the Medical Equipment industry in the United States...Actualización de narrativa • Sep 20
Expanding Spine Care And Integrated Tech Will Drive Future Opportunities
The slight increase in Alphatec Holdings’ future P/E ratio reflects higher growth expectations, which has contributed to a modest rise in its consensus analyst price target from $18.95 to $19.41. What's in the News Raised full-year 2025 revenue guidance to $742 million, up 21% year-over-year, surpassing previous forecast of $734 million.Artículo de análisis • Jul 28
Are Investors Undervaluing Alphatec Holdings, Inc. (NASDAQ:ATEC) By 43%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Alphatec Holdings fair value estimate is US$19.10 Current...Artículo de análisis • Jul 09
Should You Investigate Alphatec Holdings, Inc. (NASDAQ:ATEC) At US$11.60?
While Alphatec Holdings, Inc. ( NASDAQ:ATEC ) might not have the largest market cap around , it led the NASDAQGS...Nueva narrativa • May 27
Robotics And Minimally Invasive Techniques Will Expand Spine Care
Innovative spine solutions and expanding minimally invasive offerings position Alphatec for sustained revenue growth and margin expansion amid rising global spine care demand.Artículo de análisis • May 11
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 25% But Many Are Still Ignoring The Company
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have had a really impressive month, gaining 25% after a shaky period...Artículo de análisis • Apr 20
Alphatec Holdings (NASDAQ:ATEC) Is Making Moderate Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Mar 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Just Released Its Full-Year Results And Analysts Are Updating Their Estimates
Shareholders of Alphatec Holdings, Inc. ( NASDAQ:ATEC ) will be pleased this week, given that the stock price is up 18...Artículo de análisis • Jan 18
Alphatec Holdings, Inc. (NASDAQ:ATEC) Stock Rockets 31% But Many Are Still Ignoring The Company
Despite an already strong run, Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shares have been powering on, with a gain of 31...Artículo de análisis • Dec 19
Here's Why Alphatec Holdings (NASDAQ:ATEC) Can Afford Some Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 03
Alphatec: A Big Recovery
Summary Alphatec, a medtech company focused on spine solutions, has faced investor concerns due to continued losses, cash burn, and increasing debt despite revenue growth. Shares plunged 40% after Q2 earnings, but have recovered following the release of the third quarter results following management's comments about positive cash flow in Q4. Management's optimistic outlook is further backed up by significant improvement in EBITDA seen in 2025. Despite the positive reaction, Alphatec still needs to prove its ability to reduce debt and avoid further dilution while executing its growth plans. Read the full article on Seeking AlphaArtículo de análisis • Nov 01
Alphatec Holdings, Inc. (NASDAQ:ATEC) Soars 50% But It's A Story Of Risk Vs Reward
Alphatec Holdings, Inc. ( NASDAQ:ATEC ) shareholders would be excited to see that the share price has had a great...Artículo de análisis • Aug 29
Positive Sentiment Still Eludes Alphatec Holdings, Inc. (NASDAQ:ATEC) Following 38% Share Price Slump
The Alphatec Holdings, Inc. ( NASDAQ:ATEC ) share price has fared very poorly over the last month, falling by a...Artículo de análisis • Aug 28
We Think Alphatec Holdings (NASDAQ:ATEC) Has A Fair Chunk Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 05
Alphatec: Creating Some Real Back Pain For Its Shareholders
Summary Alphatec Holdings, Inc. experiences continued losses and dilution due to a focus on growth over margin improvements, causing concern for shareholders. Despite strong top-line growth and low sales multiples, the company's losses, cash burn, and increasing debt are worrying investors. Shares plummeted 40% after the company's second quarter results, amidst concerns about debt and limited options to finance the cash needs. Read the full article on Seeking AlphaRentabilidad de los accionistas
| ATEC | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 8.0% | 4.4% | 1.0% |
| 1Y | -33.6% | -17.9% | 28.7% |
Rentabilidad vs. Industria: Los resultados de ATEC fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -17.9% el año pasado.
Rentabilidad vs. Mercado: ATEC obtuvo unos resultados inferiores a los del mercado US, que fueron del 28.7% el año pasado.
Volatilidad de los precios
| ATEC volatility | |
|---|---|
| ATEC Average Weekly Movement | 12.7% |
| Medical Equipment Industry Average Movement | 8.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de ATEC ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ATEC(13%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1990 | 913 | Pat Miles | www.atecspine.com |
Alphatec Holdings, Inc. es una empresa de tecnología médica que diseña, desarrolla y avanza tecnologías para el tratamiento quirúrgico de trastornos de la columna vertebral en Estados Unidos y a escala internacional. La empresa fabrica y vende implantes, instrumentos, equipos de diagnóstico por imagen y piezas de recambio. Ofrece la plataforma de productos Alpha InformatiX, que incluye el sistema de imagen EOS, que permite obtener imágenes de todo el cuerpo; el sistema SafeOp Neural InformatiX, que automatiza la monitorización electromiográfica, del potencial evocado somatosensorial y del potencial evocado motor; y Valence, un sistema intraoperatorio que integra la navegación y la robótica en los procedimientos de columna vertebral, así como los sistemas Sigma Prone TransPsoas (PTP) Access y PTP Patient Positioning.
Resumen de fundamentos de Alphatec Holdings, Inc.
| Estadísticas fundamentales de ATEC | |
|---|---|
| Capitalización bursátil | US$1.27b |
| Beneficios(TTM) | -US$125.36m |
| Ingresos (TTM) | US$787.08m |
1.6x
Ratio precio-ventas (PS)-10.1x
Ratio precio-beneficio (PE)¿Está ATEC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ATEC | |
|---|---|
| Ingresos | US$787.08m |
| Coste de los ingresos | US$234.72m |
| Beneficio bruto | US$552.37m |
| Otros gastos | US$677.73m |
| Beneficios | -US$125.36m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.82 |
| Margen bruto | 70.18% |
| Margen de beneficio neto | -15.93% |
| Ratio deuda/patrimonio | 3,140.9% |
¿Cómo se ha desempeñado ATEC a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/22 18:52 |
| Precio de las acciones al final del día | 2026/05/22 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Alphatec Holdings, Inc. está cubierta por 26 analistas. 11 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Matthew Miksic | Barclays |
| Caitlin Cronin | Canaccord Genuity |
| Tao Levy | Deutsche Bank |